Trial · NCT07896564
Risk Factors for Spinal Cord Injury After Minimally Invasive Aortic Repair
NCT07896564, Not yet recruiting, Assiut University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Risk Factors for Spinal Cord Injury After Minimally Invasive Aortic Repair. Trials, record NCT07896564. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896564
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Risk Factors for Spinal Cord Injury After Minimally Invasive Aortic Repair
- NCT number
- NCT07896564
- Status
- Not yet recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Assiut University
- Conditions
- Spinal Cord Ischemia
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Postoperative Spinal Cord Ischemia | Within 30 days after the endovascular aortic intervention. | Percentage of included patients who develop postoperative spinal cord ischemia (SCI), defined as a new lower limb motor and/or sensory deficit attributed to spinal cord ischemia after other documented causes have been excluded. SCI occurrence will be determined through retrospective review of clinical and follow-up records. |
| Secondary | Neurological Recovery at Hospital Discharge | At discharge from the index hospitalization, assessed up to 90 days after the intervention. | Percentage of surviving patients with SCI whose SCI-related motor and/or sensory deficit has completely resolved at hospital discharge. Persistence of any SCI-related neurological deficit will also be recorded. |
| Secondary | Time to Spinal Cord Ischemia Onset | From the intervention through postoperative day 30. | Time in days from the endovascular aortic intervention to the first documented SCI-related neurological deficit among patients who develop SCI |
| Secondary | Neurological Deficit Severity at SCI Onset | At the first documented SCI assessment, within 30 days after the intervention. | Number and percentage of patients with SCI classified by the documented initial neurological deficit, including partial or complete loss of lower limb movement and sensory impairment. |
| Secondary | In-Hospital All-Cause Mortality | From the intervention until discharge or in-hospital death, assessed up to 90 days. | Percentage of included patients who die from any cause after the endovascular aortic intervention and before discharge from the index hospitalization. |
| Secondary | 30-Day All-Cause Mortality | Within 30 days after the intervention. | Percentage of included patients who die from any cause within 30 days after the endovascular aortic intervention, whether during hospitalization or after discharge. |
| Secondary | Overall Survival | From the intervention to death or censoring, assessed up to 60 months. | Time in months from the endovascular aortic intervention to death from any cause. Patients without a documented death will be censored at the last date they are known to be alive or the end of the observation window. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896564
GET https://conductscience.org/api/trials/v1/NCT07896564/registered